摘要
目的:对参七黄复方中的抗癌活性组分芦荟大黄素、大黄素、大黄酸、人参皂苷Rh2、槐定碱、苦参碱配伍后进行抗结肠癌的体外筛选实验,以优选最佳组分配伍。方法:采用均匀设计法设计各组分的配伍剂量,应用MTT法测定各配方对SW620细胞株增殖活性的影响,应用光学显微镜、荧光显微镜进行细胞形态学观察。结果:优选出的最佳组分配方为大黄素100μg/m L、槐定碱2000μg/m L、苦参碱2500μg/m L,对SW620结肠癌细胞抑制率达95.4%。结论:此组分配方可对结肠腺癌细胞株SW620的增殖显著抑制并诱导细胞凋亡,为进一步研发治疗结肠癌的靶向新药提供实验依据。
Objective： To find the best combination of active ingredients from Shenqihuang for Anti-colon cancer, according to screening test in-vitro on Aloe Emodin, Emodin, parietic acid, ginsenoside-rh2, Sophoridine and Matrine. Methods： By the uniform designed research, SW620 cell line was treated with constituents from shenqihuang at various concentrations; the effect on cell proliferative activity was measured by MTT assay and the effects of alkaloids against cell growth were compared. The changes of cell morphology were observed through optical microscope and fluorescence microscope. Results： The best combination of active ingredients from Shenqihuang is 100μg/mL Emodin, 2000 μg/mL Sophoridine and 2500μg/mL Matrine. The inhibition rate on SW620 cells is 95.4%. Conclusion： The compatibility can inhibit the proliferation of colon adenocarcinoma cell line SW620, and induce cell apoptosis; The results provides experimental evidence for targeting new drug research and development of traditional Chinese medicine treatment for colon cancer.
出处
《中医药导报》
2016年第9期33-36,共4页
Guiding Journal of Traditional Chinese Medicine and Pharmacy
基金
中山市科技计划项目(中科发[2010]122号)
关键词
参七黄
结肠癌
SW620
组分配伍
Shenqihuang
colon cancer
SW620
component compatibility screening
